- Thinly traded nano cap Bellerophon Therapeutics (BLPH -63.7%) dives on a 3x surge in volume, albeit on turnover of only 60K shares, in response to its announcement that its pivotal clinical trial of its Bioabsorbable Cardiac Matrix (BMC) failed to beat placebo.
- Previously: Bellerophon's Bioabsorbable Cardiac Matrix flunks clinical trial; licensor BioLineRx down 17% premarket (July 27)
Recommended For You
More Trending News
See More »